Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2001-08-31
2002-08-13
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
06433018
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to methods for reducing hypertrophy and ischemia.
An increase in the size of the heart (cardiac hypertrophy) in humans is the compensatory response of the myocardium (cardiac muscle) to increased work as a result of an increase in blood pressure or blood volume (hemodynamic overload). The myocardium can increase in size but is not capable of increasing cell number.
Two patterns of hypertrophy can occur depending on the stimulus, either pressure-overloaded hypertrophy or volume-overloaded hypertrophy. Pressure-overloaded hypertrophy typically occurs as a result of hypertension. The ventricles develop concentric hypertrophy, and exhibit an increased ratio of wall thickness to cavity radius.
Volume-overloaded hypertrophy generally occurs as a result of a defect in one of the valves of the heart. The ventricles develop hypertrophy with dilatation (eccentric hypertrophy), resulting in a proportionate increase in ventricular radius and wall thickness.
Initially, the development of cardiac hypertrophy is advantageous since it results in the addition of sarcomeres (contractile units), therefby reducing ventricular wall stress to normal levels (Ruwhof et al., (2000)
Cardio. Res
., 47:23-37). The increase in the number of sarcomeres leads to augmentation in the overall weight and size of the heart.
With prolonged hemodynamic overload, however, when the hypertrophied heart can no longer meet the increased demand in workload, the heart begins to dilate, stretching the sarcomeres and increasing the force of contraction and stroke volume. The increased stretching of the myocytes further perpetuates the hypertrophy.
Hypertrophy of the myocardium may become increasingly harmful due to the increased metabolic requirements of the enlarged heart. Molecular changes have been observed in the myocytes during development of myocardial hypertrophy. Such changes include the rapid induction of proto-oncogenes and heat shock protein genes, quantitative and qualitative changes in gene expression, and increased rate of protein synthesis (Ruwhof et al., (2000)
Cardio. Res
., 47:23-37). Changes that occur in the hypertrophied heart may contribute to the development of heart failure. Moreover, ischemic heart disease and arrhythmias may develop, increasing the risk of death.
A different type of heart disease occurs as a result of ischemia. Ischemia is an imbalance between the supply and demand of the heart for oxygenated blood. In addition to insufficient oxygen, ischemia is also caused by a reduced availability of nutrient substrates and inadequate removal of metabolites. In the majority of cases, myocardial ischemia occurs as a result of the narrowing or obstruction of an artery due to atherosclerosis. Four ischemic syndromes may result depending on the rate of development and severity of the arterial narrowing and the myocardial response. The ischemic syndromes are angina pectoris, myocardial infarction, chronic ischemic heart disease, and sudden cardiac death.
The tissue and systemic renin-angiotensin systems play a major role in regulation of pathological cardiovascular functions, such as in hypertension (Raizada et al., (1993)
Cellular and Molecular Biology of the Renin-Angiotensin System
, 515-555), left ventricular hypertrophy (Lavie et al., (1991)
Drugs
42:945-946), ischemic dilated cardiomyopathy, and heart failure Raynolds et al., (1993)
Lancet
342:1073-1075). The renin-angiotensin system also exists in other organs and tissues, including the kidneys, prostate, brain, intestines, and the vasculature.
Normal homeostatic levels of a number of hemodynamic properties, such as blood pressure, blood volume, and vascular tone, are maintained by the renin-angiotensin system. Renin is an enzyme that was first isolated from the kidneys over a hundred years ago. Angiotensinogen is cleaved by renin to yield the inactive decapeptide angiotensin I. The vascular endothelium, especially in the lungs, has an enzyme known as angiotensin converting enzyme (ACE) which cleaves off two amino acids to form the octapeptide, angiotensin II.
Angiotensin II is one component of the renin-angiotensin system that is prominently involved in virtually all aspects of the renin-angiotensin activity. The angiotensin II then exerts its effects on target organs and tissues by binding its receptor.
Binding of angiotensin II to its transmembrane domain G-protien coupled receptor (AT
1
and/or AT
2
) can activate several different intracellular signal transduction pathways that use the well-known signal transducers, such as protein kinase A, protein kinase C, MAP kinase, and src (Sadoshima et al., (1993)
Circ. Res
. 73:413-423; Duff et al., (1995)
Cardiovasc. Res
. 30:511-517; Booz et al., (1995)
Cardiovasc. Res
. 30:537-543; Schieffer et al., (1996)
Hypertension
27:476-480; Bernstein et al., (1996)
Trends Cardiovasc. Med
. 6:179-197).
In addition to these signal transduction pathways, angiotensin II also activates the Janus-associated kinase/signal transducer and activator of transcription (Jak/STAT) pathway. The components of the Jak/STAT pathway are present in a latent state in the cytoplasm of unstimulated cells. Binding of angiotensin II to its receptor leads to activation of Jak, a tyrosine kinase that phosphorylates STAT proteins and allows them to translocate to the nucleus. Within the nucleus, the phosphorylated STAT functions as a transcription factor (Ihle (1996) Cell 84:331-334) that recognizes and binds, in a sequence-specific fashion, to cis-regulatory elements in the promoter of target genes.
In mammals, the Jak family consists of Jak1, Jak2, Jak3, and Tyk2. Seven STAT proteins have been identified in mammalin cells, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6.
Jaks are crucial components of diverse signal transduction pathways that govern important cellular functions, including cell survival, proliferation, differentiation and apoptosis. Interfering with Jak activity may lead to the loss of a vital signal transduction pathway, thereby disrupting normal cellular processes needed for cell survival. Therefore, it is important to selectively inhibit particular Jaks that are involved in various disease states.
Inhibitors of Jaks include tyrphostins, which are a class of compounds that inhibit protein tyrosine kinases. The tyrosine kinases that are inhibited depends on the substituents that are present on the tyrphostin.
One particular tyrophostin, AG490, selectively inhibits Jak2 and has been proposed for treating cancer (Meydan N, et al. (1996)
Nature
379:645). Tyrphostin AG556 is a protein tyrosine kinase inhibitor that reduces myocardial damage due to ischemia (Altavilla D., et al, (2000)
Life Sciences
67:2615). However, the reference does not disclose the molecular mechanism of action of tyrphostin AG556. Furthermore, there is no indication that tyrphostin AG556 is a selective Jak2 inhibitor.
There has been an ongoing search for effective long-term treatments for myocardial dysfunction. Currently, treatments include administering drugs, such as vasiodilators, beta-blockers, free-radical scavengers, and calcium antagonists. Another type of treatment is surgery and includes by-pass surgery and angioplasty. Virtually all of these methods have performed poorly in vivo, and have been ineffective for favorable long-term results.
Cardiovascular disease is the predominant cause of death in all industrialized nations. Diseases such as diabetes, hypertension, myocardial hypertrophy, ischemia and heart failure are on the rise.
Heart muscle cannot currently be regenerated. As a consequence, affected individuals must contend with damaged heart tissue for the rest of their lives. Therefore, restoring normal cardiac function to heart muscles damaged by cardiovascular disease has been a long-term goal of cardiology.
Therefore, there is an immediate need for therapeutic agents that prevent and/or reverse the damage caused by myocardial dysfunction without harming healthy cells.
SUMMARY OF THE INVENTION
These and other objectives have been met by providing a meth
Beckles Daniel L.
Mascareno Eduardo
Siddiqui Mohammed A. Q.
Henley III Raymond
Hoffman & Baron LLP
The Research Foundation of State University of New York
LandOfFree
Method for reducing hypertrophy and ischemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing hypertrophy and ischemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing hypertrophy and ischemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2913729